Cancer is a major public health issue in Hungary; in 2019, it was the number one cause of death in Hungary. According to last year’s Eurostat statistics, the highest standardised death rates for cancer were recorded in Hungary.

It has been more than ten years that our company decided to enter the therapeutic area of oncology with generic products – György Tamás Szuhaj, Head of Oncological Business Unit said – since then, we have contributed to the recovery of cancer patients with several products, which are available in pharmacies or in hospitals. Egis was the first pharmaceutical company in Hungary to market a biosimilar product in the field of oncology, and today we provide further biosimilar products that offer cutting-edge solution for the treatment of cancer patients.”

He added: over the past decade, Egis has partnered with several professional organizations with the aim to contribute to further strengthening of patient care through joint initiatives. As for the future, Egis remains committed to maintaining its oncology portfolio.